摘要
目的:了解C-erb B-2基因在肺癌中表达的临床意义。方法:采用免疫组化方法检测42例各类型肺癌组织和10例正常肺组织中C-erb B-2基因的表达。结果:C-erb B-2基因在正常肺组织和小细胞肺癌中未见表达,在非小细胞肺癌组织中的表达率为25.71%,其中肺鳞癌表达率为6.3%,肺腺癌为50.0%,两者差异显著(P<0.05)。C-erb B-2基因在不同组织学分级中的表达差异明显(P<0.05),低分化组为70%,中分化组为13.3%,高分化组为0。而在临床分期中的表达无显著性差异(P>0.05)。结论:C-erb B-2基因在非小细胞肺癌特别是腺癌的形成和进展中发挥重要作用,C-erb B-2基因的检测可作为非小细胞肺癌患者选择个体化治疗方案的指标。
Objective To assess the clinical significance of the expression of C-erbB-2 oncogene in lung cancer. Methods Expression of C-erbB-2 was tested using immunohistochemistry method in 42 specimens of lung cancer and 10 samples of normal lung tissues. Results C-erbB-2 was unexpressed in normal lung tissues and small cell lung canc- er. The rate of C-erbB-2 oncogene expression was 25.71% in non-small cell lung cancer（NSCLC）. The positive rate of C-erbB-2 oncogene differed according to histologic type, including 50.3% of patients with adenocareinoma and 6.3% of patients with squamous cell carcinoma. Overexpression of C-erbB-2 in lung squamous cell carcinomas and adenocarcinomas had obvious difference （P 〈 0.05）. The difference was also significant （P 〈0.05） among histologic grades Ⅰ,Ⅱ and Ⅲ being 70%, 13.3%, 0 respectively. There was no significant difference （P 〉0.05） among clinical stage Ⅰ,Ⅱ and Ⅲ. Conclusion The results suggest that C-erbB-2 may play an important role in the development and progression of NSCLC, especially in lung adenocarcinoma. The detection of C-erbB-2 may be helpful to select individualized therapy project for patients with NSCLC.
出处
《东南大学学报（医学版）》
CAS
2006年第1期41-43,共3页
Journal of Southeast University(Medical Science Edition)
